Acasti Cash And Short Term Investments vs Inventory Analysis
ACST Stock | USD 2.72 0.07 2.64% |
Acasti Pharma financial indicator trend analysis is way more than just evaluating Acasti Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Acasti Pharma is a good investment. Please check the relationship between Acasti Pharma Cash And Short Term Investments and its Inventory accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acasti Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.
Cash And Short Term Investments vs Inventory
Cash And Short Term Investments vs Inventory Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Acasti Pharma Cash And Short Term Investments account and Inventory. At this time, the significance of the direction appears to have strong relationship.
The correlation between Acasti Pharma's Cash And Short Term Investments and Inventory is 0.68. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Inventory in the same time period over historical financial statements of Acasti Pharma, assuming nothing else is changed. The correlation between historical values of Acasti Pharma's Cash And Short Term Investments and Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Acasti Pharma are associated (or correlated) with its Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory has no effect on the direction of Cash And Short Term Investments i.e., Acasti Pharma's Cash And Short Term Investments and Inventory go up and down completely randomly.
Correlation Coefficient | 0.68 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Acasti Pharma balance sheet. This account contains Acasti Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Acasti Pharma fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Inventory
Most indicators from Acasti Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Acasti Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acasti Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.Selling General Administrative is likely to gain to about 9.8 M in 2024, despite the fact that Tax Provision is likely to grow to (8.2 M).
Acasti Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Acasti Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Acasti Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 22.9M | 62.5M | 128.6M | 79.1M | 91.0M | 95.5M | |
Other Current Liab | 5.6M | 1.4M | 1.5M | 3.3M | 3.8M | 2.7M | |
Total Current Liabilities | 7.4M | 1.6M | 3.3M | 3.4M | 3.9M | 3.7M | |
Total Stockholder Equity | 13.0M | 55.7M | 108.3M | 68.0M | 78.1M | 82.1M | |
Property Plant And Equipment Net | 2.1M | 86K | 315K | 567K | 652.1K | 654.3K | |
Net Debt | (14.1M) | (50.9M) | (30.0M) | (27.4M) | (24.7M) | (23.4M) | |
Retained Earnings | (126.3M) | (146.0M) | (155.8M) | (198.3M) | (178.4M) | (169.5M) | |
Cash | 14.2M | 50.9M | 30.3M | 27.9M | 32.1M | 33.7M | |
Non Current Assets Total | 6.8M | 86K | 83.1M | 49.8M | 57.3M | 60.2M | |
Cash And Short Term Investments | 14.2M | 60.7M | 43.7M | 27.9M | 32.1M | 19.2M | |
Net Receivables | 546K | 530K | 548K | 802K | 721.8K | 499.9K | |
Common Stock Shares Outstanding | 1.8M | 2.5M | 6.1M | 7.4M | 8.6M | 9.0M | |
Liabilities And Stockholders Equity | 22.9M | 62.5M | 128.6M | 79.1M | 91.0M | 95.5M | |
Other Stockholder Equity | 9.8M | 10.8M | 12.2M | 14.0M | 16.1M | 16.9M | |
Total Liab | 9.9M | 6.8M | 20.4M | 11.2M | 12.8M | 8.8M | |
Property Plant And Equipment Gross | 2.1M | 86K | 315K | 1.2M | 1.4M | 1.4M | |
Total Current Assets | 16.1M | 62.4M | 45.5M | 29.3M | 33.7M | 20.0M | |
Accumulated Other Comprehensive Income | (7.9M) | (6.3M) | (6.0M) | (6.0M) | (5.4M) | (5.2M) | |
Common Stock | 137.4M | 197.2M | 258.0M | 258.3M | 297.0M | 311.9M | |
Other Liab | 12.2M | 2.4M | 5.2M | 16.9M | 19.4M | 20.4M | |
Net Tangible Assets | 4.7M | 8.8M | 55.7M | 25.5M | 29.3M | 30.8M | |
Accounts Payable | 1.7M | 115K | 1.7M | 1.2M | 1.4M | 1.2M | |
Short Term Investments | 5K | 9.8M | 13.3M | 15K | 13.5K | 12.8K | |
Non Current Liabilities Total | 2.5M | 5.2M | 17.1M | 7.8M | 8.9M | 5.8M | |
Other Current Assets | 195K | 1.1M | 1.3M | 598K | 687.7K | 376.0K | |
Short Term Debt | 76K | 86K | 104K | 75K | 86.3K | 134.6K | |
Intangible Assets | 5.8M | 4.2M | 69.8M | 41.1M | 47.3M | 49.7M | |
Property Plant Equipment | 2.1M | 2.1M | 86K | 315K | 362.3K | 344.1K | |
Non Currrent Assets Other | 429.8K | 417.2K | 473K | 104K | 93.6K | 88.9K | |
Short Long Term Debt Total | 147K | 86K | 295K | 485K | 557.8K | 498.0K | |
Capital Lease Obligations | 147K | 86K | 295K | 485K | 557.8K | 585.6K | |
Net Invested Capital | 13.0M | 55.7M | 108.3M | 68.0M | 78.1M | 48.5M | |
Net Working Capital | 8.7M | 60.8M | 42.3M | 25.9M | 29.8M | 28.2M | |
Capital Stock | 137.4M | 197.2M | 258.0M | 258.3M | 297.0M | 208.5M |
Pair Trading with Acasti Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acasti Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acasti Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Acasti Stock
0.76 | DVAX | Dynavax Technologies | PairCorr |
0.71 | EGRX | Eagle Pharmaceuticals | PairCorr |
0.9 | BMY | Bristol Myers Squibb | PairCorr |
0.87 | CRL | Charles River Labora | PairCorr |
Moving against Acasti Stock
0.61 | MRK | Merck Company Earnings Call Today | PairCorr |
0.5 | RNAZ | Transcode Therapeutics Buyout Trend | PairCorr |
0.42 | MTD | Mettler Toledo Inter | PairCorr |
The ability to find closely correlated positions to Acasti Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acasti Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acasti Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acasti Pharma to buy it.
The correlation of Acasti Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acasti Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acasti Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acasti Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acasti Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Acasti Stock analysis
When running Acasti Pharma's price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Acasti Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acasti Pharma. If investors know Acasti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acasti Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.68) | Revenue Per Share 0.005 | Return On Assets (0.08) | Return On Equity (0.48) |
The market value of Acasti Pharma is measured differently than its book value, which is the value of Acasti that is recorded on the company's balance sheet. Investors also form their own opinion of Acasti Pharma's value that differs from its market value or its book value, called intrinsic value, which is Acasti Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acasti Pharma's market value can be influenced by many factors that don't directly affect Acasti Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acasti Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Acasti Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acasti Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.